Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2017-11, Vol.72 (5), p.e137-e138
Hauptverfasser:	Powles, Thomas, Gómez de Liaño, Alfonso, Ackerman, Charlotte
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols Double-Blind Method Humans Molecular Targeted Therapy Quinazolines Receptor, Epidermal Growth Factor Receptor, ErbB-2 Treatment Outcome Urinary Bladder Neoplasms
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!